Abbott Sample Clauses

Abbott. Where Abbott is the Other Party and Neurocrine terminated […***…] pursuant to 11.4(a), the provisions of Section 11.2(b) shall apply provided however, that if this Agreement is terminated only with respect to […***…], the provisions of Section 11.2(b) shall apply mutatis mutandis to termination by Neurocrine pursuant to this Section but only with respect to […***…].

Abbott and Iomed shall cooperate fully in estimating and scheduling production for the first firm order to be placed by Iomed. The first firm order shall cover a period of three (3) consecutive calendar months. Thereafter, firm orders shall be placed monthly and shall cover the next succeeding third month. At the time Iomed places its firm monthly orders, Iomed shall provide to Abbott Iomed's estimate of its monthly requirements for the next succeeding nine (9) calendar month 7 8 period. It is the intent that at all times Abbott shall have in hand firm monthly orders covering the current three (3) calendar month period and Iomed's estimates of its monthly requirements for the next succeeding nine (9) calendar month period.

Abbott. Metabasis hereby agrees that Sicor shall have the sole right, in its sole discretion, to initiate and control negotiations with ▇▇▇▇▇▇ Laboratories, Inc. and its Affiliates (collectively, "Abbott") regarding granting Abbott a license to the Licensed Technology. Metabasis shall not have the right to grant to Abbott a license to the Licensed Technology, or to participate in or influence any negotiations between Sicor and Abbott, without the prior written consent of Sicor.

Abbott. Abbott shall have full responsibility and discretion in conducting, including settling, any Tax Contest involving (x) any Tax for which it is responsible under Section 2.01(a), (y) any Covered Transaction Tax for which Hospira is responsible under Section 3.01(b), except as provided in paragraph (iii), below and (z) any Transition Period Tax for which Hospira is responsible under Section 3.02. Abbott shall consult in good faith with Hospira in connection with any Tax Contest described in clauses (y) or (z) of this Section 2.06(b)(ii).

Abbott. 2.2.1 Abbott will carry out process development of the selected formulation of Bulk Product on its [**] in accordance with the Development Protocol agreed between the parties and attached hereto as Appendix A. 2.2.2 Abbott will provide Barrier, or its nominee, with samples (approximately [**] kg) of Bulk Product resulting from this process development programme ("mock NDA lot") for Barrier, or its nominee, to carry out further milling and tabletting experiments. 2.2.3 Abbott will then manufacture six (6) batches of Bulk Product using the [**], each batch being [**] kg, and will supply these six (6) batches to Barrier, or its nominee, for milling and tabletting into Finished product. 2.2.4 Abbott will carry out in process controls and analytical characterization appropriate for NDA batches. Abbott will take forensic samples for the FDA and will provide such samples to Barrier or its nominee. ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 2.2.5 Abbott will provide Barrier with copies of executed batch records, including all associated documentation such as test results and any deviation reports. 2.2.6 Abbott will provide Barrier with a final development report as soon as reasonably possible after completing the development programme.

Abbott. 2.2.1 Abbott will manufacture two (2) batches of ▇▇▇▇ Product under GMP co▇▇▇▇▇▇ns for human use including mixing of raw materials and extrusion. 2.2.2 In parallel with the above step 2.2.1, Abbott will also perform [**] 2.2.3 Abbott will carry ▇▇▇ ▇▇ort term stability testing of the two (2) ba▇▇▇▇▇ of Bulk Product obtained under step 2.2.1 above [**] according to ICH conditions in bulk container packaging material. [**]

Abbott. 2.2.1 Abbott will carry out a maximum of ten different trial▇ ▇▇▇▇g its ▇▇ltrex(TM) Technology, focusing on [**] 2.2.2 Abbott will carry out preliminary stability testing of the Meltrex(T▇) formulations at [**] 2.2.3 In parallel with the above steps, Abbott will also perform process analysis of the Meltrex(TM) f▇▇▇▇▇▇tions [**]

Abbott. Abbott agrees to defend CTI and its Affiliates at its cost a▇▇ ▇▇▇en▇▇, ▇▇d will indemnify and hold CTI and its Affiliates and their respective directors, officers, employees and agents (the "CTI Indemnified Parties") harmless from and against any losses, costs, damages, fees or expenses arising out of any Third Party claim relating to (i) any breach by Abbott of any of its representations, warranties or obligations pursuant to this Agreement, or (ii) personal injury from the development, manufacture, use, sale or other disposition of Abbott Products by Abbott, its Affiliates, licensees, distributors o▇ ▇▇▇▇aborators. In the event of any such claim against the CTI Indemnified Parties by any Third Party, CTI shall promptly notify Abbott in writing of the claim and Abbott shall manage and control, at its sole expense, the defense of the claim and its settlement. The CTI Indemnified Parties shall cooperate with Abbott and may, at their option and expense, be represented in any such action or proceeding. Abbott shall not be liable for any litigation costs or expenses incurred by the CTI Indemnified Parties without Abbott prior written authorization. In addition, Abbott shall not be responsible for the indemnification of any CTI Indemnified Party arising from any negligent or intentional acts by such CTI Indemnified Party, or as the result of any settlement or compromise by the CTI Indemnified Parties without Abbott prior written consent.

Abbott. 2.2.1 Abbott will manufacture [**] Bulk Product, ▇▇ ▇▇e maximum amount tha▇ ▇▇▇ be manufactured out of the remainder material, to be used for technical assessment and further manufacturing trials including mixing of raw materials and extrusion. 2.2.2 In parallel with the above step 2.2.1, Abbott will also perform process analysis of the Meltrex(TM) formula▇▇▇▇▇ for [**]. ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.